Transparency Disclosures

Our experience has taught us that transparency in our operations can help to build trust with stakeholders. Transparency can also guard against corruption and unethical business practices. By listening and responding openly to our stakeholders’ concerns, we can improve our transparency and the way we do business.

Consistent with Lilly’s policy of open disclosure, we became the first pharmaceutical company to voluntarily launch an online clinical trial registry. Since 2002, Lilly has registered all Lilly-sponsored Phase II, Phase III and Phase IV clinical studies, conducted anywhere in the world that were initiated on or after October 15, 2002, on Additionally, Lilly began registering all Phase I clinical studies commencing on or after October 1, 2010.

In addition, we believe that transparency of business practices that involve financial payments, or other forms of value, to physicians is essential for building trust. As a result, we have taken a number of steps to provide information on important aspects of how we interact with key partners in the pursuit of advancements in medicine.

Since 1 October 2015, all member companies of Medicines Australia were required to report information relating to any healthcare professional who receives payment for consulting or speaker services and any support to attend educational events. As a member company of Medicines Australia, Lilly also provides to Medicines Australia for publication on its website:

  • A report listing health consumer organisations to which it provides financial support and/or significant direct/indirect non-financial support.

  • A report listing third party meetings and symposia to which it provides financial support.

Transparency Disclosures

For payments and transfers of value to healthcare professionals


Visit to search the database

For third party meeting sponsorship reports


For health consumer organisation support reports


Ethics & Compliance

Learn More

PP-MG-AU-0096 05/2024